borderline significancep = 0.06
Putting all these data into the context of previously published cardiovascular outcome trials which stated superiority for the majority of these drugs [ 162 , 163 , 164 ], and borderline significance ( p = 0.06) for exenatide [ 165 ], it seems that further investigations are justified to prove the beneficial impact of GLP-1 receptor agonists on EPCs.